Travere Therapeutics, Inc.

NASDAQ:TVTX

Biotechnology

Healthcare
$50.24 +1.20%

+$0.65 today

Market cap
$4.82B
Beta
1.14
P/E (TTM)
-235.0
EPS (TTM)
-$0.23
52W Low $13.97High $55.99

Volume 0.84M

Average 2.31M

TVTX Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Travere Therapeutics, Inc.NASDAQ: TVTX

Accumulated OCI · Q3 FY2026 · quarter ended Sep 2026

Accumulated OCI remains negative

Q3 FY2026 Accumulated OCI was -$2.05M, compared with -$1.05M a year earlier.

Context

  • Accumulated OCI amounted to 0.2% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
  • Accumulated OCI grew in size in 1 of the last 3 fiscal years.

What to watch

Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -94.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$2.05M-83.2% QoQ
Last fiscal yearDec 2025
-$1.19M-1386.3% YoY
Year agoSep 2025
-$1.05M-94.1% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-94.1%——
1 year-1386.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
(1.19M) USD
Year-over-year change
-1386.3%

Accumulated OCI vs competitors

How TVTX compares with its peers on the latest reported figures

  • TVTX's Sep 2026 Accumulated OCI of -$2.05M is the lowest of the 5 companies compared; the peer median is -$26.5K.
  • Its year-over-year change of -94.1% is the 2nd highest of 3, against a peer median of +1.3%.
  • Accumulated OCI amounts to 0.2% of total assets for TVTX, versus a peer median of 0.0%.
TVTX Competitors Peer median
Accumulated OCI for TVTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PHARPharming Group N.V.Mar 2026$23.75M +173.2%—4.9%
MLYSMineralys Therapeutics, Inc.Jun 2026$0 ——0.0%
PROKProKidney Corp.Mar 2026-$53K -170.7%—0.0%
MAZEMaze Therapeutics, Inc.Mar 2026-$135K ——0.0%
TVTXTravere Therapeutics, Inc.Sep 2026-$2.05M -94.1%—0.2%
Peer median (excluding TVTX) -$26.5K+1.3%—0.0%

Competitors are the stored peer set for TVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents165.75M61.69M58.18M58.54M93.04M
Short-term Investments387.13M388.56M508.68M312.17M229.76M
Net Receivables15.91M16.65M21.18M27.12M80.13M
Inventory7.31M4.52M9.41M6.2M5.88M
Other Current Assets247K15.02M19.34M12.69M28.76M
Total Current Assets582.83M486.44M616.78M416.7M437.57M
Property, Plant & Equipment (Net)34.3M30.05M25.54M19.63M14.6M
Goodwill900K800K753K753K0
Intangible Assets147.5M96.32M103.69M103.22M113.12M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets11.07M59.03M42.16M53.82M39.16M
Total Non-current Assets193.77M186.2M172.14M177.42M166.87M
Total Assets776.63M672.59M788.91M594.13M605.19M
Account Payables15.14M17.29M41.68M23.53M24.8M
Short-term Debt00068.68M0
Tax Payables00000
Deferred Revenue16.27M11.98M7.1M2.82M0
Other Current Liabilities39.59M47.99M94.32M49.46M44.71M
Total Current Liabilities124.09M142.16M177.91M200.75M159.9M
Long-term Debt226.58M375.55M377.26M310.31M311.72M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)20.38M10.93M1.84M00
Other Non-current Liabilities71.98M73.59M8.49M6.8M7.6M
Total Non-current Liabilities350.43M487.57M410.2M334.3M330.46M
Total Liabilities474.52M629.73M588.1M535.05M490.36M
Common Stock6K6K7K9K9K
Retained Earnings(765.97M)(1.01B)(1.13B)(1.45B)(1.47B)
Accumulated OCI(562K)(2.91M)(1.46M)(80K)(1.19M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity302.11M42.85M200.81M59.08M114.83M
Total Debt261.99M407.49M404.78M401.58M328.73M
Net Debt96.23M345.8M346.61M343.05M235.7M

Travere Therapeutics, Inc.

NASDAQ:TVTX

Intrinsic Alpha fair value

Locked

Current Price

$50.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.